← ANALYST RATINGS · TIPRANKS
Ionis Pharmaceuticals (IONS): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy3 Hold0 Sell
Ratings of 16 analysts in the last 3 months · top analysts only12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $82.33, the highest $100, the lowest $54.00. The average is +91.7% from the last price of $42.94.
Analyst ratings 24
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $46.00 → $88.00+91.3% | Buy | +104.9% | Upgrade | 14.10.26on TipRanks 19:50 | +3.0%next day −1.6% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $91.00 | Buy | +111.9% | Reiterated | 09.10.26on TipRanks 06:21 | +4.0%next day −3.5% · 5 days −3.2% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $100 | Buy | +132.9% | Reiterated | 08.10.26on TipRanks Oct 9 09:15 | −1.5%next day +4.0% · 5 days +2.2% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $85.00 | Buy | +98.0% | Reiterated | 08.10.26on TipRanks 21:45 | +4.0%next day −3.5% · 5 days −3.2% | ↗ |
| Justin Kim★★★★★★★★★★#1624 · hits 50% · avg +13.9% | Oppenheimer | $85.00 | Buy | +98.0% | Reiterated | 24.09.26on TipRanks 08:10 | −0.2%next day +1.0% · 5 days +0.8% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $85.00 | Buy | +98.0% | Reiterated | 24.09.26on TipRanks Sep 23 07:15 | −3.3%next day −0.2% · 5 days +2.3% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $54.00 | Hold | +25.8% | Reiterated | 23.09.26on TipRanks Sep 24 08:55 | −3.3%next day −0.2% · 5 days +2.3% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $84.00 | Buy | +95.6% | Reiterated | 23.09.26on TipRanks 14:30 | −3.3%next day −0.2% · 5 days +2.3% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $86.00 | Buy | +100.3% | Reiterated | 23.09.26on TipRanks 12:35 | −3.3%next day −0.2% · 5 days +2.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $46.00 | Hold | +7.1% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $46.00 → $44.00−4.3% | Hold | +2.5% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $48.00 → $46.00−4.2% | Hold | +7.1% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $45.00 | Hold | +4.8% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $47.00 → $45.00−4.3% | Hold | +4.8% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $48.00 → $46.00−4.2% | Hold | +7.1% | Reiterated | 23.09.26on TipRanks 12:05 | — | |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 22.09.26on TipRanks 16:07 | −3.3%next day −0.2% · 5 days +2.3% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $70.00 | Buy | +63.0% | Assigned | 22.09.26on TipRanks 07:00 | +1.9%next day −3.3% · 5 days +1.5% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $85.00 | Buy | +98.0% | Reiterated | 18.09.26on TipRanks 05:20 | −5.1%next day −0.5% · 5 days −1.1% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $89.00 → $80.00−10.1% | Buy | +86.3% | Reiterated | 14.09.26on TipRanks Sep 15 07:35 | −4.7%next day −7.7% · 5 days −14.6% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $69.00 → $56.00−18.8% | Hold | +30.4% | Reiterated | 14.09.26on TipRanks 07:35 | −4.7%next day −7.7% · 5 days −14.6% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $104 | Buy | +142.2% | Assigned | 09.09.26on TipRanks Sep 8 07:55 | −1.8%next day −0.8% · 5 days −15.6% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $87.00 → $84.00−3.4% | Buy | +95.6% | Reiterated | 08.09.26on TipRanks 13:10 | −1.8%next day −0.8% · 5 days −15.6% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $100 | Buy | +132.9% | Reiterated | 04.09.26on TipRanks Sep 7 10:15 | +0.3%next day −1.8% · 5 days −10.2% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $94.00 | Buy | +118.9% | Reiterated | 17.08.26on TipRanks 07:38 | +2.9%next day +2.4% · 5 days +7.0% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $95.00 | Buy | +121.2% | Reiterated | 14.08.26on TipRanks 12:55 | +2.6%next day +2.9% · 5 days +5.7% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $86.00 → $68.00−20.9% | Hold | +58.4% | Reiterated | 02.08.26on TipRanks 12:51 | +3.8%next day −0.7% · 5 days +2.5% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | — | Hold | — | Downgrade | 15.07.26on TipRanks 17:20 | +0.4%next day +0.5% · 5 days +3.9% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $90.00 | Buy | +109.6% | Reiterated | 15.07.26on TipRanks 09:56 | −0.8%next day +0.4% · 5 days −0.3% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $65.00 → $89.00+36.9% | Hold | +107.3% | Reiterated | 13.01.26on TipRanks Jan 14 02:16 | −2.5%next day −0.3% · 5 days +1.2% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $85.00 → $100+17.6% | Buy | +132.9% | Reiterated | 15.12.25on TipRanks 09:30 | −1.2%next day −1.5% · 5 days +1.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Ionis Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 08.10.26: target $84.00 at a price of $44.16 (+90.2%); now: $83.89 at $42.94 (+95.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 21 | 25 | 33 | 21 |
| Buy | 21 | 25 | 21 | 20 | 17 | 9 |
| Hold | 2 | 2 | 5 | 9 | 13 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.21 (from $-1.42 to $-0.96). Last quarter: $-0.69.
Sales
Next quarter’s sales estimate — $183M (from $160M to $225M). Last quarter: $268M.
Best top-analyst consensus in the sector · Healthcare
About Ionis Pharmaceuticals
- CEO: Brett Monia
- Employees: 1,480
- 2855 Gazelle Court, Carlsbad, CA, 92010, US
- www.ionis.com
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Data from the stock’s TipRanks forecast page, read 7 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗